Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Drug: Blinded (Avatrombopoag tablets)Drug: Blinded (placebo)Drug: Open Label (Avatrombopag tablets)
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00625443
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Davis, Posteraro and Wasser, MDs, LLP, Manchester, Connecticut, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT00619099
- Locations
- 🇺🇸
Landmark Medical Center, Woonsocket, Rhode Island, United States
🇺🇸Sarah Cannon Research, Nashville, Tennessee, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
- Conditions
- Obesity
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 604
- Registration Number
- NCT00603291
- Locations
- 🇺🇸
Arena Pharmaceuticals, Inc., San Diego, California, United States
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
- Conditions
- Obesity
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 4008
- Registration Number
- NCT00603902
- Locations
- 🇺🇸
Arena Pharmaceuticals, Inc., San Diego, California, United States
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT00592904
Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
- Conditions
- Neuralgia
- Interventions
- Drug: PlaceboDrug: E2007 (perampanel)
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT00592774
- Locations
- 🇺🇸
Pain and Rehabilitation Clinic of Chicago, Chicago, Illinois, United States
The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT00571064
- Locations
- 🇺🇸
Senior Care, Birmingham, Alabama, United States
🇺🇸21st Century Neurology, Phoenix, Arizona, United States
🇺🇸South Coast Clinical Trials, Anaheim, California, United States
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT00570128
- Locations
- 🇺🇸
Community Research Foundation, Miami, Florida, United States
🇺🇸Miami Children's Hospital, Brain Institute, Miami, Florida, United States
🇺🇸UCSD Pediatric Pharmacology Research Unit, San Diego, California, United States
Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00566462
- Locations
- 🇺🇸
inVentiv, The Woodlands, Texas, United States
🇺🇸Kenneth Marek, New Haven, Connecticut, United States
🇺🇸Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
- Conditions
- Epilepsy; Paediatric Partial Onset Seizures
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT00566254